Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Trial of Vigil for Participants With Ovarian Cancer
NCT02346747 · View on ClinicalTrials.gov ↗
Study Summary
The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo. The main question it aims to answer is "Will participants who receive treatment with Vigil have a longer time to disease recurrence versus the participants that were not given Vigil?"
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Vigil
Study Locations (20)
Florida
- University Of Miami Sylvester Comprehensive Cancer Center — Miami
- Moffitt Cancer Center — Tampa
- Florida Cancer Specialists — West Palm Beach
California
- Southern California Permanente Medical Group — Irvine
- Palo Alto Foundation Medical Group — San Francisco
Pennsylvania
- AMD Asplundh Cancer Pavilion — Abington
- St. Luke's Health Network — Bethlehem
Alabama
- University of South Alabama Mitchell Cancer Institute — Mobile
Georgia
- Georgia Cancer Center at Augusta University — Augusta
Kentucky
- University Of Kentucky Markey Cancer Center — Lexington
Maine
- Maine Medical Center: MMP Women's Health — Scarborough
Massachusetts
- Dana Farber Cancer Institute: Gynecologic Oncology — Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2015-02 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02346747
The ClinicalTrials.gov registry entry for NCT02346747 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gradalis, which has 5 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02346747 reports 20 study locations spanning 16 distinct geographic areas — top geographies include Florida, California, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02346747 about?
NCT02346747 is a clinical study titled "A Trial of Vigil for Participants With Ovarian Cancer". The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated with investigational product (Vigil) compared to placebo. The main question it aims to answer is "Will participants who receive treatment with Vigil have a longer time to...
What is the current status of trial NCT02346747?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2015-02. Estimated completion is 2028-12.
What conditions does trial NCT02346747 study?
This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02346747?
The interventions under investigation include: Placebo (OTHER), Vigil (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02346747?
This trial is sponsored by Gradalis, which has 5 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02346747 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.